Glasgow patient tech outfit secures £1.2m injection

Metix develops lightweight devices to monitor patients' vital signs before they reach hospital. Picture: John Devlin

A Glasgow-based company specialising in patient monitoring technology has secured a £1.2 million financial injection.

Metix said that the initial research and development (R&D) funding round had been led by UK technology and life sciences investor Deepbridge Capital. It also includes money from Scottish Enterprise and its investment arm, the Scottish Investment Bank.

• READ MORE: Technology news

Metix was founded in 2013 to develop lightweight vital sign monitors for use in the pre-hospital care environment. Its core products provide monitoring that can be used by ­paramedic, military and humanitarian workers.

The firm operates internationally, having two offices – in Glasgow and London – and a sub-assembly facility in Mexico. Its research is supported by some of the largest medical-grade sensing companies in the world.

Own an innovative start-up? Find out how to win £5,000 for your business

The funding will be directed towards further research and development as well as “enhancing regulatory compliance”. Metix also expects to increase its headcount in Glasgow with greater numbers particularly in technical and clinical validation.

• READ MORE: Health tech start-up snap40 gets £1m shot in the arm

Julio Guerrero, managing director at Metix, said: “We are pleased to have received this initial R&D funding and are delighted to have the support of Deepbridge, Scottish Enterprise and the Scottish Investment Bank.

“This support demonstrates that the technology we are developing, and have already developed, is not only a good idea but is a commercially viable proposition which can make a real difference.

“Globally, pre-hospital critical care tech is at best patchy and at worst is non-existent. We are committed to providing the technology to ensure that emergency responders anywhere in the world can have access to affordable, mobile and multi-parameter technology, which can be crucial in saving life and ensuring optimum care.”

200 Voices: find out more about the people who have shaped Scotland

Savvas Neophytou, head of life sciences at Deepbridge, added: “Metix is further developing a device which has the potential to dramatically change the pre-hospital care sector.

“As always, we have to consider the medium-long term investment returns for our investors and to this end, we believe that Metix exhibits all the qualities associated with a successful company in the medical technology sector.”

Deepbridge operates across four key divisions – disruptive tech, life sciences, renewables and sustainable technologies.

Click here to ‘Like’ The Scotsman Business on Facebook